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Background: Adherence to tuberculosis (TB) treatment is troublesome, due to long therapy duration, quick
therapeutic response which allows the patient to disregard about the rest of their treatment and the lack of
motivation on behalf of the patient for improved. The objective of this study was to develop and validate a scoring
system to predict the probability of lost to follow-up outcome in TB patients as a way to identify patients suitable
for directly observed treatments (DOT) and other interventions to improve adherence.
Methods: Two prospective cohorts, were used to develop and validate a logistic regression model. A scoring
system was constructed, based on the coefficients of factors associated with a lost to follow-up outcome. The
probability of lost to follow-up outcome associated with each score was calculated. Predictions in both cohorts
were tested using receiver operating characteristic curves (ROC).
Results: The best model to predict lost to follow-up outcome included the following characteristics: immigration
(1 point value), living alone (1 point) or in an institution (2 points), previous anti-TB treatment (2 points), poor
patient understanding (2 points), intravenous drugs use (IDU) (4 points) or unknown IDU status (1 point). Scores of
0, 1, 2, 3, 4 and 5 points were associated with a lost to follow-up probability of 2,2% 5,4% 9,9%, 16,4%, 15%, and
28%, respectively. The ROC curve for the validation group demonstrated a good fit (AUC: 0,67 [95% CI; 0,65-0,70]).
Conclusion: This model has a good capacity to predict a lost to follow-up outcome. Its use could help TB
Programs to determine which patients are good candidates for DOT and other strategies to improve TB treatment
adherence.
Keywords: Lost to follow-up outcome, Scoring system, Tuberculosis, Adherence, PredictorsBackground
The highest priority for control of tuberculosis (TB) is
to achieve an early diagnosis and satisfactory treatment
adherence [1].
To ensure satisfactory adherence, since the 1990s [2]
the World Health Organization (WHO) has recom-
mended the use of directly observed treatment (DOT).
Likewise one of components of the Stop TB Strategy is
pursuing high-quality DOT expansion and enhancement
as well as special attention to certain population groups* Correspondence: pii_tb_teresa_rodrigo@separ.es
1Programa Integrado de Investigación en Tuberculosis (PII TB) de la Sociedad
Española de Neumología y Cirugía Torácica (SEPAR), Barcelona, Spain
2Unidad de Investigación de Tuberculosis de Barcelona, Servicio de
Epidemiología de la Agencia de Salud Pública de Barcelona, Barcelona, Spain
Full list of author information is available at the end of the article
© 2012 Rodrigo et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand special situations that are associated with a higher TB
risk. The first step in addressing the needs of risk groups
is recognition and acknowledgement of their existence
and their special requirements [3]. Nonetheless it exists
still inconvenience in the implementation of DOT, since it
can be difficult and costly [4] despite evidence of cost-
effectiveness [5].
A valuable strategy to ensure treatment compliance is
to determine the patient characteristics associated with
satisfactory adherence and to identify patients who are
at risk of lost to follow-up outcome. Other methods of
control, such as early detection of patients at high risk,
also contribute to reduce this risk [6].
The objective of this study was to describe and validate
a predictive score which can be used by healthcarel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Evaluation schedule for tuberculosis patients included in the PII TB cohort (2006–2009)
1st visit 2nd visit 3rd visit 4th visit*
Diagnosis Month 2 Month 6 Month 9, 12 or 18 (optional)
Inclusion/exclusion criteria X
Sociodemographic information X
Smoking and use of alcohol X
Anthropometrics data X X X X
Clinical history X
Type of diagnostic test X
Pharmalogical treatment X X X* X
Clinical evolution X X X
Treatment adherence X X X
Sputum sample X X X X
Drug sensitivity testing X
Treatment result X X
*If treatment continued past 6 months.
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outcome of a patient at the time of diagnosis, as a way
to identify patients suitable for DOT and other interven-
tions to improve treatment adherence.
Methods
Study setting
A multi-centered, national and population-based
prospective study, comprised of derivation and valid-
ation cohorts, was performed involving 43 collaborating
professionals at 35 healthcare centers in Spain from
January 1, 2006 to December 31, 2009.
Case identification and follow-up
The study included all patients, diagnosed with TB over
18 years of age with smear-positive TB, or smear-
negative sputum with a culture positive for Mycobacterium
tuberculosis, extrapulmonary TB disease with caseating
granuloma identification by histology, and patients with
clinical, radiological, epidemiological or laboratory suspi-
cion of TB, for whom the clinician prescribed anti-TB
treatment and was followed until the end of treatment. A
verbal consent form, approved by our Research Ethics
Committee (see below), was dictated to the patient and
signed by the treating physician.
Exclusion criteria included patients with known drug
resistance and those with a contraindication to start
standard treatment of three or four drugs.
The cases follow-up was according to an evaluation
schedule (Table 1).
Patient information was prospective and stored in
an electronic case report form with a standardized
questionnaire generated for each patient in the entire
cohort and available online, with a username andpassword specified for each collaborating study inves-
tigator. The program was tested for three months and
some changes and eliminations were made before the
study. The data manager was responsible for review-
ing and completing anomalous or missing data. Inves-
tigators and clinicians communicated about case
report completion and the database by means of tele-
phone and email.
The database contained information regarding
sociodemographics, smoking habits and alcohol use,
anthropometric information, clinical history, diagnostic
methods, drug sensitivity testing, pharmalogical treat-
ment, clinical evolution, and treatment adherence and
outcome. Living situation was considered “alone” when
the patient had housing and “institutionalized” when
the patient lived in a closed institution, such as a resi-
dence hall, prison, mental hospital, etc. Country of ori-
gin was classified as native or immigrant. We did not
classify immigrants into sub-groups because of the great
diversity in country of origin and the few number of
cases from each country. The variable "understanding"
was systematically reviewed for each patient by a phys-
ician based on the presence of linguistic or cultural
barriers.
Lost to follow-up outcome (defaulter in the past) was
defined according to European recommendations [7,8]
as interruption of treatment for any reason for more
than two months, non-completion of treatment within
9 months when the patient is placed on a six-month
regimen, or drug intake of < 80% of the prescribed dose.
The derivation cohort included patients diagnosed
with TB between January 1, 2006 and February 28, 2007
and compared subjects who completed treatment to lost
to follow-up subjects (those who died or moved during
Table 2 Comparison of the clinical and epidemiological characteristics of the derivation and validation cohorts
Variables Total Derivationa Validationa p-valueb
N (%) N (%)
Country: 0.002
Spain 2080 (67.6%) 1048 (70.3%) 1032 (65.1%)
Other 995 (32.4%) 442 (29.7%) 553 (34.9%)
Understanding: 0.003
Good 2566 (91.7%) 1266 (90.1%) 1300 (93.3%)
Poor 232 (8.29%) 139 (9.89%) 93 (6.68%)
Living situation: 0.250
Alone 312 (10.5%) 157 (10.7%) 155 (10.3%)
Homeless or institutionalized 92 (3.10%) 54 (3.69%) 38 (2.52%)
Group 376 (12.7%) 189 (12.9%) 187 (12.4%)
Family 2191 (73.7%) 1062 (72.6%) 1129 (74.8%)
Intravenous drug use: <0.001
No 1399 (45.5%) 872 (58.5%) 527 (33.2%)
Yes 49 (1.59%) 21 (1.41%) 28 (1.77%)
Unknown 1627 (52.9%) 597 (40.1%) 1030 (65.0%)
Age (years): 0.449
18-30 986 (32.3%) 497 (33.4%) 489 (31.3%)
31-50 1233 (40.4%) 596 (40.0%) 637 (40.8%)
>50 834 (27.3%) 397 (26.6%) 437 (28.0%)
Human immunodeficiency virus infection: <0.001
No 2284 (74.3%) 1060 (71.1%) 1224 (77.2%)
Yes 148 (4.81%) 66 (4.43%) 82 (5.17%)
Unknown 643 (20.9%) 364 (24.4%) 279 (17.6%)
Use of directly observed treatment: 0.017
No 2626 (91.1%) 1338 (89.8%) 1288 (92.4%)
Yes 258 (8.95%) 152 (10.2%) 106 (7.60%)
Sex: 0.476
Male 1945 (64.0%) 920 (63.4%) 1025 (64.7%)
Female 1092 (36.0%) 532 (36.6%) 560 (35.3%)
Country- Healthcare <0.001
Primary care 511 (17.1%) 268 (18.0%) 243 (16.1%)
Urgent care 1461 (48.8%) 682 (45.8%) 779 (51.7%)
Specialist 476 (15.9%) 210 (14.1%) 266 (17.7%)
Unknown' 548 (18.3%) 330 (22.1%) 218 (14.5%)
Employment: <0.001
Disabled 98 (3.39%) 68 (4.70%) 30 (2.08%)
Employed 1781 (61.6%) 901 (62.3%) 880 (60.9%)
Unemployed 547 (18.9%) 257 (17.8%) 290 (20.1%)
Retired 464 (16.1%) 220 (15.2%) 244 (16.9%)
Previous anti-tuberculosis treatment: 0.304
No 2728 (91.5%) 1320 (91.0%) 1408 (92.1%)
Yes 252 (8.46%) 131 (9.03%) 121 (7.91%)
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Table 2 Comparison of the clinical and epidemiological characteristics of the derivation and validation cohorts
(Continued)
Lost to follow-up outcome 0.974
No 2814 (93.5%) 1332 (93.5%) 1482 (93.5%)
Yes 195 (6.48%) 92 (6.46%) 103 (6.50%)
aData from the derivation group was used to create the model and data from the validation group was used to valídate the model.
bp values according to χ2 test with correction for continuity.
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treatment were not included). The validation cohort was
comprised of patients diagnosed with TB between March
1, 2007 and December 31, 2009, based on similar simple
size to the derivation cohort; no patients were excluded
from the validation group because their outcome was
unknown at the time of inclusion.
According to the International Directives for Ethical
Review of Epidemiological Studies (Council for the
International Organizations of Medical Sciences, Geneva
1991) and to recommendations about ethical aspects of
epidemiological research by the Spanish Epidemiology
Society, this study about predicting factors of bad adher-
ence to TB treatment (derivation cohort) was approved
by the Research Ethics Committee of Teknon Medical
Center, Barcelona. All information that identified the
study subjects was confidential and was managed
according to Law 15/1999 Protection of Data about
Personal Character.
The investigators do not have conflicts of interest.Data analysis
A bivariate analysis was used to identify the risk factors
associated with lost to follow-up outcome for the
derivation cohort, comparing subjects who were cured
plus those who completed treatment to lost to follow-up
subjects. All variables without presence of colinearity
were included in the logistic regression model using the
stepwise method to determine predictors of lost to
follow-up outcome (p≤ 005). Odds ratio (OR) with a
95% confidence intervals (CI) was calculated as a meas-
urement of association. Patients with the lowest rates of
lost to follow-up outcome were considered the reference
category. P-values equal to or below 005 were considered
statistically significant.
Independent predicting factors were assigned a
point value by dividing its coefficient from the logistic
regression by a lowest coefficient and rounded to the
nearest whole number. Each patient was assigned a
total number of points and a predictor value using
the model for anti-TB lost to follow-up outcome.
Sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) were calculated
for each possible value.Reliability (concordance between predicted and observed
results) was analyzed in the following manner:
 By comparing coefficients from the regression
model, which adjusted the validation group to the
original derivation model using a z-score test.
 By grouping patients by terciles of predicted risk and
comparing each tercil of predicted of lost to follow-up
outcome with observed lost to follow-up outcome.
Goodness of fit was assessed using the Hosmer-
Lemeshow test.
 The model’s discrimination was analyzed by using
receiver operating characteristics (ROC) curves [9]
to compare the distribution of predictors for
subjects who did and did not lost to follow-up
outcome. The curves were constructed from the
point intersection of the derivation and validation
groups. Area under the curve (AUC) with 95% CI
was calculated for both ROC curves to determine if
the predicting model was better than one due to
chance.
Analyses were performed using SPSS statistical pack-
age, version 18.0 (SPSS Inc, Chicago, IL USA) and R
statistical package, version 2.8.1 (The R Foundation for
Statistical Computing, Vienna, Austria). The χ2 test was
used to compare qualitative variables and Fisher’s exact
test was used when expected values were less than 5.
EpiR [10] was used to calculate diagnostic tests.Results
A total of 3079 subjects were included in the study:
1490 subjects in the derivation cohort and 1589 subjects
in the validation group. Table 2 provides a summary of
the characteristics and risk factors associated with poor
adherence of both groups. The lost to follow-up out-
come was similar between the derivation and validation
cohorts (6.4% vs 6.5%; p = 0.974).Derivation model cohort
The following independent predictors of lost to follow-up
outcome were identified from the multivariate analysis:
country of residence, living alone, living in an institution,
previous anti-TB treatment, poor patient understanding,
Table 3 Prognostic score for lost to follow-up outcome according to a multivariate analysis of the derivation cohort
Variables β Se (β) p-value ORa 95% CIb Scorec
Country of origin Immigrant 0.71 0.330 0.031 2.03 (1.06 - 3.88) 1
Living situation Alone 0.85 0.410 0.037 2.35 (1.05 - 5.26) 1
Institution 1.56 0.515 0.002 4.79 (1.74 - 13.14) 2
Previous treatment Yes 1.03 0.395 0.009 2.80 (1.29 - 6.08) 2
Understanding Poor 1.07 0.363 0.003 2.93 (1.44 - 5.98) 2
Intravenous drug use Yes 2.25 0.642 <0.001 9.51 (2.70 - 33.47) 4





cRegression coefficient divided by the lowest value coefficient (0.64), rounded to the nearest whole number; used to determine the point value assigned to each
independent predictor.
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Using the logistic regression coefficients, 4 points were
assigned to IDU subjects, 2 points were assigned to those
living in an institution, those who had previously received
anti-TB treatment and with poor understanding, and one
point was assigned to immigrants, patients who lived
alone and those with an unknown IDU status. A score of
11 points represented the worst prognosis for treatment
compliance (Table 3).
Sensitivity, specificity, PPV and NPV results can be
found in Table 4. Note the positive relationship between
PPV and the point score.
Validation cohort
A multivariate analysis was performed to estimate the
coefficients of the above predictors of lost to follow-up
outcome. No statistically significant differences existed
between coefficients of each cohort, except for unknown
IDU status (Table 2).
Similar results were observed for sensitivity, specificity,
PPV and NPV tests (Table 4).
We were unable to use deciles of risk for the Hosmer-
Lemeshow test of the derivation cohort because someTable 4 Score evaluation for derivation and validation group
Derivation groupa
Predictive score Sensitivity Specificity PPVb
≥ 0 100.00 0.00 6.5
≥ 1 83.70 54.65 11.3
≥ 2 46.74 80.71 14.3
≥ 3 34.78 90.54 20.3
≥ 4 13.04 97.30 25.0
≥ 5 7.61 98.80 30.4
aThe derivation group included 1490 patients and the validation group included 15
bPPV: positive predictive value (probability of lost to follow-up outcome).
cNPV: negative predictive value (probability of no lost to follow-up outcome).expected values were under 5. Therefore, observed and
expected values were grouped into 3 categories, which
were found to be similar (p = 0.209).
Area under the ROC curve for the derivation and
validation groups were 0.73 (95% IC of 0.70-0.75) and
0.67 (95% IC of 0.65-0.70), respectively (Figure 1). No
statistically significant differences were noted.
The probability of lost to follow-up outcome by observed
score can be found in Table 5. Increasing risk of lost to
follow-up outcome corresponds to an increased score
(p<0.001).
As seen in Table 6, a score of 2 or more points can be
considered criteria for DOT implementation, which
represents 28.2% of our study population or 56.4% of the
subjects with a lost to follow-up outcome. A score of 3
or more points represents 11.1% of our study population
and 30.2% of those with lost to follow-up outcome.
Discussion
As our study results show, we were able to obtain and
validate a predictive score for TB treatment adherence
for a large cohort of new TB cases undergoing standard
TB treatment. The score could be easy for a clinician tos
Validation groupa
NPVc Sensitivity Specitifity PPV NPV
. . ... 100.00 0.00 6.5 . . ...
98.0 93.20 16.69 7.2 97.3
95.6 65.05 67.36 12,1 96.5
95.3 26.21 89.84 15.2 94.6
94.2 11.65 95.76 16.0 94.0
93.9 4.85 98.99 25.0 93.8
89 patients.
Figure 1 Receiver operating characteristics curves: comparison between derivation and validation cohorts.
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diagnosis because the evaluation of it is dependent on
only clinical and epidemiological characteristics, not
on results of complimentary tests. The results of the
statistical model indicate this predicting system is valid to
evaluate the probability of lost to follow-up outcome be-
fore treatment is even initiated, as shown by the positive
relationship between rate of lost to follow-up and point
score.
Other components of the Stop TB Strategy are
contributing to health system strengthening and
engaging all care providers [3] but the implementation
of DOT is not possible in many countries and is not the
rule in developed countries. This TB score is a useful to
determine the proportion of patients for who DOT
should be considered, depending of available resources
of the TB program.Table 5 Probability of lost to follow-up outcome for tuberculo
predictive score (2006–2009)
Predictive score Lost to follow-up outcome / Total Rate of
0b 22 / 998 2.2
1 63 / 1163 5.4
2 51 / 516 9.9
3 35 / 213 16.4
4 12 / 80 15
5 12 / 43 28
aOR: odds ratio, CI: confidence interval b Reference category: indicates unable to calThe independent predictors factors of lost to follow-
up outcome such as living situation or previous TB
treatment were also consistent to those of other studies
[11-13]. Other predictive models have been created in
recent years have to estimate the risk of certain diseases
[14-17], including some for TB (on quality of respiratory
health [18], preventative isolation [19], severity pulmon-
ary TB by means of chest x-ray [20], clinical course [21]
and risk of multi-drug resistance [22]), but to our know-
ledge none have been created for the risk of lost to
follow-up outcome.
Our score takes into account some characteristics,
such as country of origin. Some studies have shown
that the immigrant patient population does not meet
the treatment adherence objectives described by the
WHO, but the native patient population does [23].
Furthermore, the percentage of annual TB casessis patients in the PII TB cohort according to their
lost to follow-up outcome (%) OR (95% CI)a p value
1 . . ...
2.54 (1.55 - 4.15) <0.0001
4.86 (2.91 - 8.11) <0.0001
8.72 (4.99 - 15.22) <0.0001
7.82 (3.71 - 16.49) <0.0001
17.17 (7.80 - 37.80) <0.0001
culate.
Table 6 Percentage of total patients undergoing directly observed therapy and proportion of lost to follow-up
patients according to their predictive score
Predictive score % patients undergoing DOT % lost to follow-up patients in DOT
≥ 0 100 100
≥ 1 66.8 88.7
≥ 2 28.2 56.4
≥ 3 11.1 30.2
≥ 4 4.0 12.3
≥ 5 1.4 6.1
DOT: Directly Observed Therapy.
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higher [24-27]. Thus it is important a predictive score
that provides the probability of lost to follow-up out-
come at the time of diagnosis considers characteristics
such as country of residence, living alone or in an in-
stitution, history of TB or IDU, or poor understanding.
It should be noted that poor patient understanding
refers to not only a language barrier, but also difficulty
in understanding treatment instructions which can
occur in native and immigrant population [24].
According to our model, the probability of lost to
follow-up outcome corresponds with a significantly
elevated risk of all point categories and also increases
with the total points acquired by each patient. Our
analyses that examined concordance between the
predicted and observed values yielded similar results and
the CI of the ROC curves did not detect any significant
differences. This confirms the reliability and discrimin-
ation capacity of our model.
Treatment adherence is directly related to many
factors, such as gender, poverty, economic difficulty,
social context, healthcare services, personal interpret-
ation of the disease [28], drug addiction, country of
origin [29], history of TB [23], alcoholism, homelessness
and HIV infection [30]. The score of our model allows a
clinician to determine which TB patients have a higher
risk of lost to follow-up by a simple score ≥2. The
clinician can then decide what measure should be taken
to improve treatment adherence [21], such as scheduling
additional clinical visits, providing more information
about TB, providing family or social support, reducing
drug prescription costs, hasten future clinical visits,
improving communication between involved healthcare
professionals, collaborating with public health personnel
or community health workers [31] and finally accurately
allocating DOT resources to the patients who need it
the most.
Systematic DOT is a proven effective intervention
to achieve treatment adherence [32]. For example,
treatment compliance rates have reached over 95% insubgroups for which DOT was made a priority [33]. As
consequence of that DOT is more costly than
self-administered treatment [5], all TB control programs
must use efficiently their resources.
The score estimated in our study reflects the study
setting, with a high quality and uniform healthcare
system throughout the country. The score calculated in
other settings may vary according to different patient
characteristics and healthcare systems. In the setting of
limited healthcare distribution, the score can represent
the side of the medal dedicated to healthcare and can
indicate where improvements should be made. Current
studies such as this should be reviewed by control
programs to facilitate the use of predicting factors of
treatment non-compliance to identify high risk
subgroups. A predictive score can be extremely helpful
to best direct DOT interventions.
One study limitation is that patients with known drug
resistance and those with a contraindication to start
standard treatment of three or four drugs were excluded
because the first study cohort (derivation cohort) was
also used to study treatment completion among TB
patients [23]. Patients with known drug resistance were
excluded because they required longer treatment, had
poor compliance and represented few cases, which could
have distorted the results.
Consequently, the second cohort (validation cohort)
also followed the same exclusion criteria. Other
limitation is the use of terciles of risk for the Hosmer-
Lemeshow test instead of deciles of risk because of an
insufficiently large sample size. Nonetheless, we still
consider the model valid because the observed and
expected values were similar.
Conclusion
We have described a predictive model to classify and
grade the risk of anti-TB lost to follow-up outcome.
Given adequate funding, our model will aid in the
identification of patients in need of DOT and other
interventions to improve treatment adherence.
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